A paper titled "Head to head comparison of 68Ga-NGUL and 68Ga-PSMA-11 in patients with metastatic prostate cancer: a prospective study" is published in JNM. This prospective study revealed that 68Ga-NGUL, a novel prostate specific membrane antigen (PSMA) targeting PET tracer, has a similar ability to detect primary and metastatic lesions compare to 68Ga-PSMA-11 which is the most well established PSMA PET tracer.